Farxiga® (dapagliflozin) – New indication
May 5, 2020 - FDA announced the approval of AstraZeneca’s Farxiga (dapagliflozin), to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (New York Heart Association [NYHA] class II-IV) with reduced ejection fraction.
Top